# SAB Biotherapeutics, Inc. (SABS) stock price

URL: https://funkfolio.com/stock/SABS

> SAB Biotherapeutics, Inc. (SABS) trades at $2.92 and is worth $263.06M. Valuation against its own history and up to 20 years of financials.

---

## SAB Biotherapeutics, Inc. (SABS)

SAB Biotherapeutics, Inc. (SABS) is a healthcare company (biotechnology) based in the United States. The share price is $2.92, down 2.67% on the day, which values the company at $263.06M. Price as of 17 Nov 2026, 19:29 UTC, from Yahoo Finance.

### Key facts

- **Share price:** $2.92 −2.67% today
- **Market value:** $263.06M
- **200-week average:** $4.33 33% below
- **Sector:** Healthcare

Figures as of 17 Nov 2026, 19:29 UTC. Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

### SAB Biotherapeutics, Inc. in more detail

SABS trades at -3.1× next year's expected earnings. It sits 33% below its 200-week average of $4.33.

In its favour: More cash than debt. Worth checking: Share count keeps rising; Thin interest cover.

1 of the superinvestors tracked here hold SABS, including Peter Kolchinsky (0.1% of the portfolio).

### Superinvestors holding SABS

1 of the investors tracked here report a position in their latest 13F filing.

- [Peter Kolchinsky RA Capital Management](https://funkfolio.com/gurus/peter-kolchinsky) 0.15% of portfolio · $17.2M · Q2 2026

### SAB Biotherapeutics, Inc. (SABS): questions and answers

**What is SAB Biotherapeutics, Inc.'s market cap?**

SAB Biotherapeutics, Inc. is valued at $263.06M at a share price of $2.92.

**Is SABS above its 200-week moving average?**

No. SABS is 32.5% below its 200-week average of $4.33. Long-term investors watch that line because strong companies rarely trade below it for long.

**Does SABS pay a dividend?**

SAB Biotherapeutics, Inc. does not currently pay a regular dividend.

**Which famous investors own SABS?**

In their latest quarterly filings, Peter Kolchinsky (0.1% of the portfolio) hold SABS. These filings are published up to 45 days after each quarter ends, so positions may have changed since.

### Learn to read these numbers

[All stocks guides →](https://funkfolio.com/learn/stocks)

- [Altman Z-score: formula, zones and where it fails](https://funkfolio.com/learn/stocks/altman-z-score)

  The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- [Analyst price targets and ratings: what they mean](https://funkfolio.com/learn/stocks/analyst-price-targets)

  An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
- [Free cash flow and FCF yield explained](https://funkfolio.com/learn/stocks/free-cash-flow)

  Free cash flow is the cash a business generates from operations minus what it spends on equipment, buildings and other long-lived assets. Free-cash-flow yield divides that cash by the company's market value: $5 billion of free cash flow on a $100 billion company is a 5% yield. It is cash available to owners and lenders, not profit.

### Cite this page

Funkfolio, “SAB Biotherapeutics, Inc. (SABS) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/SABS

Underlying data: Yahoo Finance; company filings with the SEC.
